StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

Investment analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

Bio-Path Stock Down 7.5 %

NASDAQ BPTH opened at $0.19 on Friday. The firm’s 50-day moving average is $0.85 and its two-hundred day moving average is $0.95. Bio-Path has a 12 month low of $0.12 and a 12 month high of $9.80.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.